Evidence map›Paper›PMID 29723215›Full record

ArticlePloS one2018

Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data.

Tianyu Zhang, Jielin Xu, Siyuan Deng, Fengqi Zhou, Jin Li, Liwei Zhang, Lang Li, Qi-En Wang, Fuhai Li

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024
    Review
  5. BaySyn: Bayesian Evidence Synthesis for Multi-system Multiomic Integration.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2023
    Article
  6. Review
  7. New Predictive Biomarkers for Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Presence and role of stem cells in ovarian cancer.World journal of stem cells · 2019
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Tianyu ZhangDepartment of BioMedical Informatics (BMI), The Ohio State University, Columbus, Ohio, United States of America.
Jielin XuDepartment of BioMedical Informatics (BMI), The Ohio State University, Columbus, Ohio, United States of America.
Siyuan DengDepartment of BioMedical Informatics (BMI), The Ohio State University, Columbus, Ohio, United States of America.
Fengqi ZhouDepartment of BioMedical Informatics (BMI), The Ohio State University, Columbus, Ohio, United States of America.
Jin LiDepartment of BioMedical Informatics (BMI), The Ohio State University, Columbus, Ohio, United States of America.
Liwei ZhangSchool of Mathematical Sciences, Dalian University of Technology, Dalian, China.
Lang LiDepartment of BioMedical Informatics (BMI), The Ohio State University, Columbus, Ohio, United States of America.
Qi-En WangDepartment of Radiology, The Ohio State University, Columbus, Ohio, United States of America.
Fuhai LiDepartment of BioMedical Informatics (BMI), The Ohio State University, Columbus, Ohio, United States of America.ORCID 0000-0002-3773-146X
The Ohio State University · USDalian University of Technology · CN

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Averting recurrent and resistant ovarian tumorsR01CA211175 · NCI · OHIO STATE UNIVERSITY · PI WANG, QIEN · 2017 to 2021
$2.3M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA211175
6 · The paper itself

Abstract

Tumor recurrence occurs in more than 70% of ovarian cancer patients, and the majority eventually becomes refractory to treatments. Ovarian Cancer Stem Cells (OCSCs) are believed to be responsible for the tumor relapse and drug resistance. Therefore, eliminating ovarian CSCs is important to improve the prognosis of ovarian cancer patients. However, there is a lack of effective drugs to eliminate OCSCs because the core signaling pathways regulating OCSCs remain unclear. Also it is often hard for biologists to identify a few testable targets and infer driver signaling pathways regulating CSCs from a large number of differentially expression genes in an unbiased manner. In this study, we propose a straightforward and integrative analysis to identify potential core signaling pathways of OCSCs by integrating transcriptome data of OCSCs isolated based on two distinctive markers, ALDH and side population, with regulatory network (Transcription Factor (TF) and Target Interactome) and signaling pathways. We first identify the common activated TFs in two OCSC populations integrating the gene expression and TF-target Interactome; and then uncover up-stream signaling cascades regulating the activated TFs. In specific, 22 activated TFs are identified. Through literature search validation, 15 of them have been reported in association with cancer stem cells. Additionally, 10 TFs are found in the KEGG signaling pathways, and their up-stream signaling cascades are extracted, which also provide potential treatment targets. Moreover, 40 FDA approved drugs are identified to target on the up-stream signaling cascades, and 15 of them have been reported in literatures in cancer stem cell treatment. In conclusion, the proposed approach can uncover the activated up-stream signaling, activated TFs and up-regulated target genes that constitute the potential core signaling pathways of ovarian CSC. Also drugs and drug combinations targeting on the core signaling pathways might be able to eliminate OCSCs. The proposed approach can also be applied for identifying potential activated signaling pathways of other types of cancers.

Indexed as

Biomarkers, TumorFemaleGenomicsHumansNeoplasm Recurrence, LocalNeoplastic Stem CellsOvarian NeoplasmsSignal TransductionTranscription FactorsBiomarkers, TumorTranscription Factors

Identifiers

PMID29723215
PMCPMC5933740
OpenAlexW2802334156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.